Metachronous primary esophageal squamous cell carcinoma and duodenal adenocarcinoma: A case report and review of literature

Table 2 Laboratory date

Date	Reference range	February 19, 20211	March 31, 20212	October 8, 20213	December 7, 20214	January28, 20225	May 14, 20226
CA72-4 (u/mL)	0-6.9	1.64	19.1	6.48	8.61	74.6	227
CEA (ng/mL)	0-5	2.54	2.29	2.79	14.6	47.1	742
AFP (ng/mL)	0-5	16.6	18.8	17.2	18.3	16.2	10.8
NLR	-	7.25	1.47	1.76	2.21	2.21	15.89
LMR	-	1.29	4.07	3.34	2.37	2.37	1.3
PLR	-	376.72	220.86	305.44	278.89	278.89	258.46
IL-6 (pg/mL)	0-5.3	-	-	7.18	7.12	27.82	918.02
IL-8 (pg/mL)	0-20.6	-	-	9.55	10.21	17.73	230.94
ω-3-C22:5 (μmol/L)	0.74-3.11	-	-	0.448	0.529	0.348	0.295
ω-6-C22:5 (μmol/L)	0.37-1.86	-	-	0.293	0.193	0.138	0.136
ω-6/ω-3	< 10	-	-	13.68	18.75	27.01	8.04
UDCA (nmol/L)	40-758	-	-	4.6	4.7	11.3	13.9

¹Preoperative.

²After surgery.

³After three cycles of “DP” chemotherapy.

⁴After two cycles of “XELOX” chemotherapy.

⁵After two cycles of immunotherapy.

⁶2 mo after giving up treatment.

CA72-4: Carbohydrate antigen 72-4; CEA: Carcinoembryonic antigen; AFP: Alpha-fetoprotein; NLR: Neutrophil-lymphocyte ratio; LMR: Lymphocyte-monocyte ratio; PLR: Platelet-lymphocyte ratio; IL-6: Interleukin-6; IL-8: Interleukin-8; UDCA: Ursodeoxycholic acid.